[(2S)-3-hydroxy-2-(octadec-9-enoylamino)propyl] dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: [(2S)-3-hydroxy-2-(octadec-9-enoylamino)propyl] dihydrogen phosphate
• 化学式: C₂₁H₄₂NO₆P
• 分子量: 435.5
• InChiKey: OTPODXRPJGBQEK-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• DRUG DELIVERY PROMOTER CONTAINING SUBSTANCE FOR ACTIVATING LYSOPHOSPHOLIPID RECEPTORS
  申请人：Osaka University

  公开号：EP3135297A1

  公开（公告）日：2017-03-01

  The present invention provides a drug delivery enhancer comprising, as an active ingredient, a substance that activates a lysophospholipid receptor, the enhancer being intended to be used for enhancing the delivery of a therapeutic drug for a disease involving abnormal blood vessel formation to an affected area; a pharmaceutical composition for treating a disease involving abnormal blood vessel formation, the composition comprising, as an active ingredient, a substance that activates a lysophospholipid receptor; and a method for screening for a therapeutic drug for a disease involving abnormal blood vessel formation, the method comprising selecting a substance that activates a lysophospholipid receptor specifically expressed in vascular endothelial cells of an affected area.

  本发明提供了一种药物递送增强剂，其活性成分包括一种可激活溶血磷脂受体的物质，该增强剂旨在用于增强治疗涉及异常血管形成的疾病的药物向受影响区域的递送；一种用于治疗血管异常形成疾病的药物组合物，该组合物作为活性成分包括一种能激活溶血磷脂受体的物质；以及一种用于筛选血管异常形成疾病治疗药物的方法，该方法包括选择一种能激活在受影响区域的血管内皮细胞中特异表达的溶血磷脂受体的物质。
• LEUKOCYTE INFILTRATION PROMOTER AND TUMOR IMMUNOACTIVATOR
  申请人：Osaka University

  公开号：EP3357512A1

  公开（公告）日：2018-08-08

  A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.

  溶血磷脂受体激活物质能够使肿瘤中的异常血管正常化，而不影响正常血管，从而诱导或促进白细胞浸润整个或部分肿瘤区域。因此，这种溶血磷脂受体激活物质可用作白细胞浸润促进剂和抗肿瘤免疫刺激剂。此外，这种溶血磷脂受体激活物质与癌症免疫疗法结合使用时，可增强癌症免疫疗法，因此可用作增强癌症免疫疗法的制剂。
• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF
  申请人：Ludwig Institute for Cancer Research, Ltd.

  公开号：EP2654779B1

  公开（公告）日：2018-02-28
• DRUG DELIVERY ENHANCER COMPRISING SUBSTANCE FOR ACTIVATING LYSOPHOSPHOLIPID RECEPTORS
  申请人：Osaka University

  公开号：US20170112861A1

  公开（公告）日：2017-04-27

  The present invention provides a drug delivery enhancer comprising, as an active ingredient, a substance that activates a lysophospholipid receptor, the enhancer being intended to be used for enhancing the delivery of a therapeutic drug for a disease involving abnormal blood vessel formation to an affected area; a pharmaceutical composition for treating a disease involving abnormal blood vessel formation, the composition comprising, as an active ingredient, a substance that activates a lysophospholipid receptor; and a method for screening for a therapeutic drug for a disease involving abnormal blood vessel formation, the method comprising selecting a substance that activates a lysophospholipid receptor specifically expressed in vascular endothelial cells of an affected area.